[
  {
    "ts": null,
    "headline": "Patient Capital Management Q2 2025 Investment Review",
    "summary": "Patient Capital Management Q2 2025 Investment Review",
    "url": "https://finnhub.io/api/news?id=d865c91a71641dde5c43cd76de6c0a10f08334174afe2cecf528161a1612ab6b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752420840,
      "headline": "Patient Capital Management Q2 2025 Investment Review",
      "id": 135912682,
      "image": "",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d865c91a71641dde5c43cd76de6c0a10f08334174afe2cecf528161a1612ab6b"
    }
  },
  {
    "ts": null,
    "headline": "Why Novartis Is Still A 'Buy' After 15% Surge",
    "summary": "Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks. Find out why NVS stock is a buy.",
    "url": "https://finnhub.io/api/news?id=ed6b3e9c41c0c4097ff67891dd2e8c7caf7cf443c0fb78ffe110c1c84137ab35",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752403500,
      "headline": "Why Novartis Is Still A 'Buy' After 15% Surge",
      "id": 135910850,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1644466793/image_1644466793.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks. Find out why NVS stock is a buy.",
      "url": "https://finnhub.io/api/news?id=ed6b3e9c41c0c4097ff67891dd2e8c7caf7cf443c0fb78ffe110c1c84137ab35"
    }
  }
]